Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-κB Pathway Activity: A Novel Approach to a Long-Standing Enigma.

cluster analysis epithelial ovarian cancer high-grade serous ovarian cancer progression-free survival signal transduction pathways

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Sep 2020
Historique:
received: 04 08 2020
revised: 09 09 2020
accepted: 11 09 2020
entrez: 23 9 2020
pubmed: 24 9 2020
medline: 24 9 2020
Statut: epublish

Résumé

We investigated signal transduction pathway (STP) activity in high-grade serous ovarian carcinoma (HGSC) in relation to progression-free survival (PFS) and overall survival (OS). We made use of signal transduction pathway activity analysis (STA analysis), a novel method to quantify functional STP activity. Activity of the following pathways was measured: androgen receptor (AR), estrogen receptor (ER), phosphoinositide 3-kinase (PI3K), Hedgehog (Hh), Notch, nuclear factor-kappa B (NF-κB), transforming growth factor beta (TGF-β), and Wnt. We selected HGSC samples from publicly available datasets of ovarian cancer tissue, and used repeated

Identifiants

pubmed: 32961868
pii: cancers12092660
doi: 10.3390/cancers12092660
pmc: PMC7564278
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Medical Research and Materiel Command
ID : DAMD17-01-1-0729
Organisme : National Health and Medical Research Council
ID : ID199600
Organisme : National Health and Medical Research Council
ID : ID400413
Organisme : National Health and Medical Research Council
ID : ID400281
Organisme : National Health and Medical Research Council
ID : ID 310670
Organisme : National Health and Medical Research Council
ID : ID 628903
Organisme : Cancer Institute NSW
ID : ID 12/RIG/1-17
Organisme : Cancer Institute NSW
ID : 15/RIG/1-16

Références

Am J Cancer Res. 2015 Apr 15;5(5):1602-9
pubmed: 26175931
Mol Med Rep. 2019 Jun;19(6):4529-4535
pubmed: 30942405
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443240
Am J Pathol. 2018 Sep;188(9):1956-1972
pubmed: 30030980
Sci Signal. 2015 Nov 03;8(401):pe3
pubmed: 26535006
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832253
Int J Mol Sci. 2013 Apr 15;14(4):8213-27
pubmed: 23591839
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Lung Cancer. 2002 Aug;37(2):153-9
pubmed: 12140138
Clin Cancer Res. 2012 Mar 1;18(5):1374-85
pubmed: 22241791
Br J Cancer. 2020 Sep;123(5):785-792
pubmed: 32507853
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Cancer Ther. 2020 Feb;19(2):680-689
pubmed: 31727690
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Oncotarget. 2014 Jul 30;5(14):5196-7
pubmed: 25114037
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Clin Cancer Res. 2009 Sep 1;15(17):5404-13
pubmed: 19690197
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
J Cell Physiol. 2019 Jun;234(6):8381-8395
pubmed: 30417375
Cold Spring Harb Perspect Med. 2015 Apr 01;5(4):
pubmed: 25833940
Sci Rep. 2019 Feb 7;9(1):1603
pubmed: 30733525
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50
pubmed: 16912992
Bioinformatics. 2005 Sep 15;21(18):3683-5
pubmed: 16076888
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6
pubmed: 19256737
BMC Clin Pathol. 2014 Oct 22;14:42
pubmed: 25349530
Gynecol Oncol. 2019 Feb;152(2):426-433
pubmed: 30503267
J Cell Immunol. 2020;2(2):68-73
pubmed: 32395722
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64
pubmed: 25850553
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Int J Mol Sci. 2018 Sep 19;19(9):
pubmed: 30235830
Int J Gynecol Pathol. 2000 Jan;19(1):7-15
pubmed: 10638449
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644
EMBO J. 2020 Mar 16;39(6):e104013
pubmed: 32009247
Oncotarget. 2016 Sep 13;7(37):60310-60331
pubmed: 27531891
OMICS. 2006 Fall;10(3):358-68
pubmed: 17069513
Hum Pathol. 2005 Oct;36(10):1108-12
pubmed: 16226111
Cancers (Basel). 2019 Aug 07;11(8):
pubmed: 31394751
J Cell Biochem. 2016 Jun;117(6):1279-87
pubmed: 26774024
Nature. 2015 Sep 3;525(7567):119-23
pubmed: 26266985
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2014 Dec 15;20(24):6618-30
pubmed: 25316818
Ann Oncol. 2010 Mar;21(3):488-492
pubmed: 19887463
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
BMC Cancer. 2016 Aug 02;16:582
pubmed: 27484466
Cancer. 2010 Jul 1;116(13):3276-84
pubmed: 20564628
Cancer Res. 2014 Jun 1;74(11):2936-45
pubmed: 24695361

Auteurs

Laura van Lieshout (L)

Department of Obstetrics and Gynecology, Catharina Cancer Institute, Catharina Hospital, 5602ZA Eindhoven, The Netherlands.
Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Radboud University Medical Center, 6500HB Nijmegen, The Netherlands.

Anja van de Stolpe (A)

Precision Diagnostics, Philips Research, 5656AE Eindhoven, The Netherlands.

Phyllis van der Ploeg (P)

Department of Obstetrics and Gynecology, Catharina Cancer Institute, Catharina Hospital, 5602ZA Eindhoven, The Netherlands.

David Bowtell (D)

Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne 3000, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney 2145, Australia.

Joanne de Hullu (J)

Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Radboud University Medical Center, 6500HB Nijmegen, The Netherlands.

Jurgen Piek (J)

Department of Obstetrics and Gynecology, Catharina Cancer Institute, Catharina Hospital, 5602ZA Eindhoven, The Netherlands.

Classifications MeSH